Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDX-010 and Peptide Vaccine in Resected Stage III/IV Melanoma
NCT00084656Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2004
- Primary completion
- Oct 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ipilimumab in melanoma, sponsored by Bristol Myers Squibb. Started May 2004; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00084656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084656.